A practical reference on REV-ERB agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-04. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Drostanolone propionate produces considerably less virilization in women compared to equal doses of testosterone propionate. However, since the given dosage for breast cancer was relatively high (200 mg/twice a week), mild virilization including oily skin, acne, voice deepening, hirsutism, and clitoral enlargement could still occur, and marked virilization could manifest with long-term therapy. The drug has no estrogenic activity and hence has no propensity for causing gynecomastia (in males) or fluid retention. Drostanolone propionate is not known to pose a risk of hepatotoxicity.
=== United Arab Emirates === The United Arab Emirates has long been known as a hub of illicit financial flows and corruption. A large number business, real estate and financial transactions of the country majorly involve some sort of illegal activity. Moreover, several corrupt and criminal actors from across the world operate through or from the Emirates, including European money launderers, Nigerian kleptocrats, East African gold smugglers, Afghan warlords and others. Even the royal family members of the UAE are often known to be associated with certain cases of offshore holdings. However, in 2022, the UAE fell into a risk of being named in the Financial Action Task Force (FATF) "grey list". The list defines nations determined to have "strategic deficiencies" in combating money laundering and terrorist financing. On 4 March 2022, FATF placed the UAE in its 'grey' list of countries that are subject to increased monitoring. In April 2020, the Emirates had been warned of its money laundering activities, where FATF called the UAE's limited prosecutions on the issue a "concern". In November 2021, the group received a report from the Emirates, which did not reach much of the thresholds required for avoid the grey list. A report in June 2023 revealed that the Western countries, including Germany, Italy, Greece and the U.S., had been pushing FATF to remove the UAE from its grey list on money laundering, despite the Emirates’ image of being a haven for illicit flows.
Hydrazones are the basis for various analyses of ketones and aldehydes. For example, dinitrophenylhydrazine coated onto a silica sorbent is the basis of an adsorption cartridge. The hydrazones are then eluted and analyzed by high-performance liquid chromatography (HPLC) using a UV detector. The compound carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (abbreviated as FCCP) is used to uncouple ATP synthesis and reduction of oxygen in oxidative phosphorylation in molecular biology. Hydrazones are the basis of bioconjugation strategies. Hydrazone-based coupling methods are used in medical biotechnology to couple drugs to targeted antibodies (see ADC), e.g. antibodies against a certain type of cancer cell. The hydrazone-based bond is stable at neutral pH (in the blood), but is rapidly destroyed in the acidic environment of lysosomes of the cell. The drug is thereby released in the cell, where it exerts its function.
Sources: en.wikipedia.org
IR4: Infrared detector for composition and concentration measurements in polyolefins for gel permeation chromatography (GPC/SEC), HPLC, TREF, etc. IR5: an infrared detector for highly demanding applications in Polymer Char instruments such as GPC-IR, HPLC, CFC and other separation techniques. Part of the techniques and instruments were developed with Petrochemical companies and Research Institutes from United States, Belgium, Finland, Germany and Japan. The company supplies in over 35 countries around the globe Analytical Services for Polymer characterization.
The king cobra (Ophiophagus hannah) is a species complex of snakes endemic to Asia. With an average length of 3.18 to 4 m (10.4 to 13.1 ft) and a record length of 5.85 m (19.2 ft), it is the world's longest venomous snake and among the heaviest. Under the genus Ophiophagus, it is not phylogenetically a true cobra despite its common name and some resemblance. Spanning from the Indian subcontinent through Southeastern Asia to Southern China, the king cobra is widely distributed albeit not commonly seen. Individuals have diversified colouration across its habitats, from black with white strips to unbroken brownish grey, although after taxonomic re-evaluation, it is no longer the sole member of its genus but is now a species complex; these differences in pattern and other aspects may cause the genus to be split into at least four species, spread across its large geographic range. It chiefly hunts other snakes, including those of its own kind, although other lizards and rodents are also occasional prey. This is the only ophidian that constructs an above-ground nest for its eggs, which are purposefully and meticulously gathered and protected by the female throughout the incubation period. Typical threat display of this elapid includes neck-flap spreading, head raising, hissing and sometimes charging. Capable of striking at a considerable range and height with an immense venom yield, envenomation from this species may induce rapid onset of neurotoxic and cytotoxic symptoms, requiring prompt antivenom administration.
==== Apixaban binding to factor Xa ==== Apixaban shows a similar binding mode as rivaroxaban and forms a tight inhibitor-enzyme complex when connected to FXa. The p-methoxy group of apixaban connects to S1 pocket of FXa but does not appear to have any interaction with any residues in this region of FXa. The pyrazole N-2 nitrogen atom of apixaban interacts with Gln-192 and the carbonyl oxygen interacts with Gly-216. The phenyl lactam group of apixaban is positioned between Tyr-99 and Phe-174 and due to its orientation, it is able to interact with Trp-215 of the S4 pocket. The carbonyl oxygen group of the lactam moiety interacts with a water molecule and does not seem to interact with any residues in the S4 pocket.
Sources: en.wikipedia.org
=== Judicial === The Rhodesian High Court's nine Appellate and General Division judges initially neither rejected UDI nor openly supported it. The Chief Justice Sir Hugh Beadle, of the Appellate Division, announced simply that the judges would go on carrying out their duties "according to the law". This originally noncommittal stance evolved over time, largely pivoting around legal cases argued at the High Court in Salisbury between 1966 and 1968. The first of these, Madzimbamuto v. Lardner-Burke N. O. and Others, concerned Daniel Madzimbamuto, a black Rhodesian who was detained without trial by the Rhodesian government on 6 November 1965, the day after the declaration of a state of emergency and five days before UDI, on the grounds that he might pose a danger to the public. Desmond Lardner-Burke, the Rhodesian Minister of Justice and Law and Order, prolonged the state of emergency in February 1966, prompting Madzimbamuto's wife to appeal for his release, arguing that since the United Kingdom had declared UDI illegal and outlawed the Rhodesian government with the Southern Rhodesia Act 1965, the state of emergency (and, by extension, Madzimbamuto's imprisonment) had no legal basis. The General Division of the Rhodesian High Court ruled on 9 September 1966 that legal sovereignty lay with the British government, but that to "avoid chaos and a vacuum in the law" the Rhodesian government should be considered to be in control of law and order to the same extent as before UDI.
=== Tissue type === Cutaneous flaps contain the full thickness of the skin, fat, and superficial fascia and are used to fill small defects. These are typically supplied by a random blood supply. Examples include Z-plasty, deep inferior epigastric perforator (DIEP) flaps, and V-Y advancement flaps. Fasciocutaneous flaps contain subcutaneous tissue and deep fascia, resulting in a more robust blood supply and ability to fill a larger defect. The Cormack and Lamberty classification is used for the vascular supply of fasciocutaneous flaps. Examples include emporoparietal and anterolateral thigh fasciocutaneous flaps, lateral fasciocutaneous flaps and posterior fasciocutaneous flaps.
Latex can trigger an IgE-mediated cutaneous, respiratory, and systemic reaction. The prevalence of latex allergy in the general population is believed to be less than one percent. In a hospital study, 1 in 800 surgical patients (0.125 percent) reported latex sensitivity, although the sensitivity among healthcare workers is higher, between seven and ten percent. Researchers attribute this higher level to the exposure of healthcare workers to areas with significant airborne latex allergens, such as operating rooms, intensive-care units, and dental suites. These latex-rich environments may sensitize healthcare workers who regularly inhale allergenic proteins. The most prevalent response to latex is allergic contact dermatitis, a delayed hypersensitivity reaction that manifests as dry, crusted lesions. This reaction usually lasts 48–96 hours. Sweating or rubbing the area under the glove aggravates the lesions, possibly leading to ulcerations. Anaphylactic reactions occur most often in sensitive patients who have been exposed to a surgeon's latex gloves during abdominal surgery, but other mucosal exposures, such as dental procedures, can also produce systemic reactions. Latex and banana sensitivity may cross-react. Furthermore, those with latex allergy may also have sensitivities to avocado, kiwifruit, and chestnut. These people often have perioral itching and local urticaria. Only occasionally have these food-induced allergies induced systemic responses.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.